Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Trastuzumab biosimilars(Herzuma), Gedatolisib
Sponsor: Korean Cancer Study Group